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Macrophages (MØ) and mononuclear phagocytes are major targets of infection by dengue virus (DV), a mosquito-
borne flavivirus that can cause haemorrhagic fever in humans. To our knowledge, we show for the first time that the
MØ mannose receptor (MR) binds to all four serotypes of DV and specifically to the envelope glycoprotein. Glycan
analysis, ELISA, and blot overlay assays demonstrate that MR binds via its carbohydrate recognition domains to
mosquito and human cell–produced DV antigen. This binding is abrogated by deglycosylation of the DV envelope
glycoprotein. Surface expression of recombinant MR on NIH3T3 cells confers DV binding. Furthermore, DV infection of
primary human MØ can be blocked by anti-MR antibodies. MR is a prototypic marker of alternatively activated MØ, and
pre-treatment of human monocytes or MØ with type 2 cytokines (IL-4 or IL-13) enhances their susceptibility to
productive DV infection. Our findings indicate a new functional role for the MR in DV infection.
Citation: Miller JL, deWet BJM, Martinez-Pomares L, Radcliffe CM, Dwek RA, et al. (2008) The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog
4(2): e17. doi:10.1371/journal.ppat.0040017
Introduction
Dengue is the most prevalent mosquito-borne viral disease
worldwide and in the past 40 years has undergone a global
resurgence such that almost half the world’s population are
currently living at risk in dengue-endemic areas [1]. There is a
spectrum of disease severity following dengue virus (DV)
infection that in its more severe forms results in dengue
haemorrhagic fever (DHF) and shock syndrome. The resul-
tant morbidity and mortality, and subsequent considerable
economic burden, make the development of a safe and
effective vaccine imperative. DV pathogenesis is complex and
multifactorial [2], and macrophages (MØ) are thought to play
an important role in disease both as primary targets of viral
infection and as a source of immunomodulatory cytokines.
The four serotypes of DV (DV1-DV4) bind to a number of
opsonic and non-opsonic receptors on cells of the mono-
nuclear phagocyte lineage including DC-SIGN [3,4], glyco-
saminoglycans [5], and when in complex with speciﬁc
antibody, Fc and complement receptors [6].
MR is a multi-domain protein that is composed of a
cysteine-rich (CR) domain which has lectin activity and binds
to sulphated sugars, a ﬁbronectin type-II (FNII) domain that
mediates binding to collagen [7] and eight C-type-lectin-like
domains (or carbohydrate-recognition domains, CRD). The
fourth CRD mediates most of the speciﬁcity of these domains
for glycans terminating in mannose, fucose and N-acetyl
glucosamine. In addition to many endogenous ligands, MR
binds to bacteria (e.g. Mycobacterium tuberculosis), fungi (e.g.
Pneumocystis carinii) and viruses (e.g. HIV). MR is constitutively
internalized from the plasma membrane by clathrin-medi-
ated endocytosis and recycled back to the cell surface.
Intracellular targeting is mediated by a tyrosine-based motif
in the cytoplasmic tail, although it contains no recognised
signalling motifs (for a comprehensive review see [8]). DC-
SIGN, a lectin with similar sugar speciﬁcity to that of the MR,
can mediate DV attachment to dendritic cells [3,4]. Even
though DV binding to DC-SIGN on these cells is important
for attachment, DC-SIGN-mediated viral endocytosis is not
required for DV entry [9].
While the immune response to viruses is classically
described as Th1 mediated, the literature in the case of DV
suggests that this may not be absolute. IgE (characteristic of a
Th2 environment) has recently been shown to be elevated in
the acute stages of DV infection [10] and at defervesence [11].
A microarray study of whole blood gene expression during
secondary DV infection has shown early upregulation of IL-
13 transcripts in acute samples from DHF patients [12]. This
suggests that a Th2 response may be occurring in patients at
some stages of infection. Indeed, studies of IL-12, IL-13 and
TGFb cytokine levels in DHF patients suggest that the DV
response shifts from a Th1-dominant response to a Th2-
biased response during disease progression [13,14]. The
immune responses in infants/neonates differ qualitatively
from those of adults, with the immature immune system
having a bias towards Th2 rather than Th1 immune
responses, presenting a particularly relevant challenge for
pediatric DV vaccination [15].
MØ are profoundly inﬂuenced by the cytokine proﬁle in
their immediate environment. Functionally diverse subsets of
alternatively or classically activated mononuclear phagocytes
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or IL-13 elicits an ‘alternate type of activation’, as opposed to
the classical activation induced by IFNc [16]. These alter-
natively activated cells have been implicated to have
regulatory functions in cellular and humoral immunity by
affecting the balance of pro- and anti-inﬂammatory reactions
[17]. Protein expression studies and transcriptional proﬁling
have shown that IL-4 induces upregulation of several
receptors, including the mannose receptor (MR) on mono-
cytes and MØ [18,19].
In this study we show that MR binds to DV grown in
mosquito cells and to recombinant mammalian cell–pro-
duced DV envelope glycoprotein. A recombinant MR fusion
protein (CRD4–7-Fc) was shown to recognize DV envelope (E)
protein in ELISA and blot overlays, and binding was inhibited
by mannose, fucose and EDTA. The presence of MR on
transfected cells is sufﬁcient to confer DV binding. DV
infection of MØ was blocked by antibodies against the human
MR suggesting that it is a novel functional receptor
contributing to DV infection. We also show that pre-
treatment of primary human monocytes with Th2 cytokines
(IL-4/IL-13), which upregulate MR expression, increases their
susceptibility to DV infection in vitro. Better understanding
of receptor/s and entry pathways mediating infection in
humans could be crucial to the design and safety of a dengue
vaccine.
Results
Soluble MR Binds Mosquito Cell–Derived DV and
Recombinant Soluble E Protein
The ability of MR to bind DV antigen produced in
mosquito (C6/36) and human (293T) cells was examined.
ELISA wells were coated with semi-puriﬁed C6/36-grown DV2
or recombinant soluble E (sE) protein produced in the
endothelial kidney cell line 293T (see below for character-
isation of this reagent) and probed with the entire extrac-
ellular region of the murine MR expressed with an HA tag or
recombinant truncated forms of the murine MR with human
Fc tags. MR-HA bound to puriﬁed mosquito cell–derived DV2
(Figure 1A) and to sE (Figure 1B), and binding was mediated
speciﬁcally by CRD4–7 and not the CR or the FNII domains.
Binding of CRD4–7-Fc to both C6/36-grown DV2 (Figure 1C)
and sE (Figure 1D) was inhibited by 2mM D-mannose, 2mM L-
fucose, and to a lesser extent 2mM D-galactose, and depended
on the presence of divalent cations. This is consistent with the
known sugar speciﬁcity and calcium dependence of the MR
CRD4–7 domains.
We extended the study by investigating the binding of
CRD4–7-Fc to mosquito cell–derived virus of the other 3 DV
serotypes (DV1, DV3 and DV4) and to mammalian (Vero)
cell–grown DV2 by ELISA. CRD4–7-Fc bound to all four
serotypes of DV in a dose-dependent manner (Figure 1E).
Binding of the CRD4–7-Fc correlated with the different
coating levels of these antigens as determined with an
antibody against all 4 DV serotypes (Figure 1F). In addition,
we tested whether CRD4–7-Fc and sMR-HA interacted with
other ﬂaviviruses. ELISA data showed that both CRD4–7-Fc
and MR-HA both bound to Japanese encephalitis virus
(inactivated vaccine antigen) and tick-borne encephalitis
virus (inactivated, mouse brain-grown) (data not shown).
The speciﬁcity of MR CRD4–7-Fc binding to DV sE was
further examined by blot overlay. CRD4–7 bound exclusively
to a single band that migrated at 52 kDa (Figure 2A, left-hand
lane). This band was recognized by the anti-E protein
antibody, 3H5, when blots were stripped and reprobed
(Figure 2B, left-hand lane), conﬁrming that CRD4–7 binds
to DV E-protein. CRD4–7 did not bind sE deglycosylated with
peptide:N-glycosidase F (PNGaseF) (Figure 2A, right-hand
lane), in contrast to 3H5 that bound to both the native and
the deglycosylated forms of the protein (Figure 2B), indicat-
ing that CRD4–7 binds speciﬁcally to N-linked glycans on sE.
Binding of CRD4–7 to sE was inhibited by the presence of
either 2mM D-mannose, 2mM L-fucose or 20mM EDTA. The
presence of sE on these blots was conﬁrmed by washing blots
and reprobing in the absence of inhibitors (data not shown).
In addition, CRD4–7-Fc did not bind to unglycosylated
domain III of DV E protein produced in bacteria in ELISA
experiments (data not shown).
Given the interaction of DV with MR described above, it
was important to characterise the glycans on the human cell–
produced sE, especially since we are unaware of any similar
analysis in the literature. This reagent is valuable, as its glycan
modiﬁcations may more closely resemble the patterns found
on viral particles produced during infection in the human
host compared with baculovirus and E. coli produced
molecules. DV E protein has two conserved N-linked
glycosylation sites at Asn-67 and Asn-153. Deglycosylation
of sE by PNGaseF led to a shift in apparent mobility on SDS-
PAGE from 52 kDa to 46 kDa (the predicted molecular weight
of sE is 45 kDa), indicating that the protein carries N-linked
glycan modiﬁcations (Figure 3A and 3B). Conversely, diges-
tion of sE by endoglycosidase H, which cleaves high mannose
oligosaccharides, did not result in a mobility shift on SDS-
PAGE (Figure 3B). RNAse B was deglycosylated by both
enzymes under corresponding reaction conditions as a
positive control (data not shown). A more speciﬁc glycan
analysis by sequential digestion with sialidase, fucosidase and
mannosidases (Figure 3C) showed approximately 40% of the
glycoforms were sialylated and 25% contained a1–3,4 linked
outer arm fucose. There was no evidence of terminal
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Author Summary
Dengue disease and its severe manifestations are a growing public
health concern, with a third to half the world’s population living in
dengue-endemic areas. In recent years there have been significant
advances in understanding dengue virus (DV) interactions with
target cells such as macrophages, dendritic cells, hepatocytes, and
endothelial cells. Interaction with and infection of these cells leads
to the production of new virions as well as immune mediators,
which can shape the course of the subsequent immune response.
The vascular leakage associated with dengue haemorrhagic fever is
believed to be immune mediated. Our work on the interaction of DV
with human macrophages has led to two major findings; first, we
have identified that the macrophage mannose receptor is important
for mediating the infection of human macrophages by DV, and
second, that the type 2 cytokines IL-4 and IL-13 enhance macro-
phage susceptibility to DV infection. DV–receptor interactions are of
critical importance for understanding not only the mechanisms of
entry, but also the biology of infection and the pathogenesis.
Understanding the immunopathogenesis of dengue disease is
crucial to the development of both a safe dengue vaccine and
therapeutic inhibitors of early DV replication.Figure 1. MR Binding to DV Is Mediated by the CRD4–7
(A) Binding of MR extracellular domain (MR-HA) and chimeric MR fusion protein constructs to mosquito cell–derived (C6/36) NGC strain DV2 and (B)
soluble E protein (sE) produced in a human cell line, detected by ELISA. Closed bars, DV antigen; open bars, uncoated wells. The MR-HA protein was
detected with an anti-murine MR antibody (MR5D3). Binding of the Fc fusion proteins to the DV/sE was detected with an anti-Fc antibody. (C) Inhibition
of CRD4–7-Fc binding to mosquito cell–derived semi-purified DV2 and (D) sE, detected by ELISA as above. (E) Binding of CRD4–7-Fc to all four serotypes
of DV, detected with an anti-Fc antibody. Strains examined were mosquito cell (C6/36)–derived virus of DV1 (Hawaii), DV2 (NGC), DV3 (H-87) and DV4
(H-241), and Vero cell–grown DV2 (16681). Differential binding to the serotypes may reflect coating levels, as indicated by (F) binding of rabbit anti-
DV1–4 antibody. Normal rabbit immunoglobulin (RIg) was included as a control and both were detected with an anti-rabbit antibody. The low levels of
CRD4–7-Fc binding to C6/36-grown DV2 in this panel reflect a shorter development time than in the other panels. Data are expressed as mean and SD
of triplicate wells. Representative data from two to five independent experiments are shown. Recombinant fusion proteins contain the cysteine-rich (CR)
domain, fibronectin type-II (FNII) domain, and various carbohydrate-recognition domains (CRD) of the MR.
doi:10.1371/journal.ppat.0040017.g001
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Mannose Receptor Mediates Dengue Infectionmannose. The glycans were also processed by weak anion
exchange (WAX) HPLC before and after sialidase digestion.
There were charged glycoforms remaining after sialidase
digestion which may be sulphated (data not shown).
Cell Surface MR Expression Confers DV Binding
To further evaluate MR as a potential DV receptor, we
examined binding of DV to human MR-transfected 3T3 cells
(3T3.hMR). As DC-SIGN has previously been shown to be an
important attachment receptor for DV, DV binding to
3T3.hMR cells was compared with binding to 3T3 cells
transfected with DC-SIGN. Initially we conﬁrmed expression
of the respective receptors on the 3T3 cell surface (Figure 4A
and 4B). To assess virus binding, cells were incubated with
mosquito cell–grown DV, unbound virus was washed away
and DV bound to the cells was detected with the anti-E
protein antibody, 3H5 (Figure 4C–4E). Histograms show a
clear shift in ﬂuorescent intensity indicating DV binding to
cells transfected with either human MR or DC-SIGN. Similar
data were observed using anti-pre-membrane glycoprotein
(prM) antibody (2H2; data not shown) to detect bound DV.
Thus, surface expression of human MR on transfected 3T3
cells was sufﬁcient to confer DV binding.
Type 2 Cytokines Enhance MØ Susceptibility to DV
Infection
A human primary cell culture assay system was established
in which we examined the functional role of MR and the
effects of cytokines on the susceptibility of mononuclear
phagocytes to DV infection. Monocytes were puriﬁed from
human PBMC fractions and cultured for 2 or 7 d to prepare
monocyte-derived MØ (MDMØ) or differentiated into mono-
cyte-derived dendritic cells (MDDC) prior to infection. The
percentage of cells infected was quantiﬁed by microscopy by
staining nuclei with DAPI and viral antigen with the anti-
DV2 E protein monoclonal antibody, 3H5. MDDC were more
susceptible to infection by DV (percent infected DC: 12.3%
þ/  7.1) compared with either 2 or 7 d differentiated MDMØ
in the absence of added cytokine (percent infected 2 d
MDMØ: 1.8% þ/  0.7; 7 day MDMØ: 1.1% þ/  0.3) from the
same donor (3 donors), using a multiplicity of infection of
0.4. The presence of DV non-structural protein in infected 2
d MDMØ using anti-NS1 monoclonal antibodies (obtained
from Eva Harris) suggested that active viral replication and
de novo viral protein production, rather than mere uptake
of viral antigen, was occurring (data not shown). Plaque
assays on supernatants from infected primary 2 or 7 d
MDMØ cell cultures conﬁrmed the occurrence of productive
infection, with viral titres increasing over time and reaching
10
4 pfu/ml in cell supernatants 2 d after infection of 6 3 10
6
cells.
Considering that MDDC, which were grown in an IL-4/GM-
CSF cytokine cocktail, were infected to a higher degree than
the MDMØ, various cytokines were tested for their ability to
alter the susceptibility of MDMØ to DV infection by pre-
incubation with monocytes for 48 h prior to DV infection
(see Table S1 for full list and concentrations). Only the type 2
cytokines IL-4 and IL-13, which utilize a common receptor
chain, had a substantial effect on the susceptibility of MDMØ
to DV infection in culture (Figure 5A and 5B), increasing the
percentage of infected cells from around 1% to between 4%
and 21% (Figure 5C). An almost 6-fold average increase in
the percentage of cells infected was observed for 8
independent donors (p ¼ 0.005). IL-4 may also contribute
to the enhanced degree of DV infection of MDDC, as GM-
CSF alone did not increase the level of infection of MDMØ
(Table S1).
Neither the age of the cells nor the length of treatment
altered the enhancing effects of IL-4. Enhanced susceptibility
to DV infection was seen when monocytes were allowed to
differentiate into MØ over 7 d, and then treated with IL-4 for
48 h prior to DV infection (day 9 MDMØ, Figure 5D). An 8-
fold increase in the percentage of infected cells was observed
for 3 independent donors (p¼0.03). Alternatively, monocytes
treated for 2–7 d with IL-4 prior to infection with DV all
showed similar heightened susceptibility (data not shown).
This suggested that the increased number of infected cells
was not due to maturation of the cells. A dose response
experiment indicated that the enhancement of DV infection
of MDMØ could be achieved with as little as 1.5ng/ml IL-4
(data not shown).
The interaction of DV with primary cells appears to be
multifactorial, as we found variability between donors and
receptor expression level. Surface expression of both MR and
DC-SIGN is upregulated on MDMØ by IL-4 treatment (Figure
6A and 6B), consistent with previous data for DC-SIGN on
human monocytes [20] and for MR on primary mouse MØ
[19,21]. While the fold increase in surface MR levels following
IL-4 treatment (4.1–fold þ/ 1.3) parallels the fold increase in
the percent of infected cells (4.6-foldþ/ 1.4), from analysis of
Figure 2. MR CRD4-7-Fc Binds Specifically to sE in Blot Overlay, and
Binding Depends on N-Linked Sugars
sE and PNGaseF-treated sE were resolved by SDS-PAGE using 10% gels,
transferred to nitrocellulose membranes, and (A) probed with MR CRD4–
7-Fc. (B) Blots were subsequently stripped and reprobed with the anti-E
protein antibody, 3H5.
doi:10.1371/journal.ppat.0040017.g002
PLoS Pathogens | www.plospathogens.org February 2008 | Volume 4 | Issue 2 | e17 0004
Mannose Receptor Mediates Dengue Infectiona limited number of donors no clear correlation can be
drawn between the two. This is also true of the relationship
between upregulation of surface DC-SIGN expression (7.7-
foldþ/ 0.9) on the same IL-4-treated cells and increase in the
percent of infected cells (mean of 4 donors; data not shown).
Anti-MR Antibodies Block DV Infection in Human MØ
The functional role of MR in DV infection of primary
human MØ was investigated using a polyclonal anti-MR
antibody to block infection. This was examined in the IL-4-
treated MDMØ since these cells showed the highest rate of DV
Figure 3. Production and Characterisation of Recombinant Soluble Dengue Virus E-Glycoprotein
(A) SDS-PAGE of sE protein preparation resolved on 10% gel and stained with Coomassie Brilliant Blue. Lane 1, sE preparation as eluted from NiNTA-
agarose. Lane 2, PNGaseF-treated sE. Lane 3, PNGaseF alone.
(B) Western blot of sE before (Lane 1) and after treatment with PNGaseF (Lane 2) or EndoH (Lane 3), resolved under reducing conditions by 10% SDS-
PAGE, and probed with the anti-DV E monoclonal antibody, 3H5.
(C) NP HPLC chromatograms of the complete pool of 2AB labelled glycans of sE glycoprotein, together with sequential digestions. a) Complete glycan
pool, undigested, with structural representation of A2G2S2. b) Glycans digested with Arthrobacter ureafaciens sialidase (abs), which releases a2–6 and 3
linked sialic acids. Boxed sections show peaks containing a1–3 or 4 linked fucose residues, with structural representations of A2G2 and A2FG2. c)
Glycans digested with abs and almond meal fucosidase (amf), which releases a1–3 and 4 linked fucose residues.
Key: A2, biantennary; G, galactose; F, fucose; S, sialic acid. Filled square, N-acetyl glucosamine; open circle, mannose; open diamond, galactose; filled
star, sialic acid; open diamond with dot, fucose. The solid lines are b-linkage, dotted lines are a-linkage, and curved lines are unknown linkage.
doi:10.1371/journal.ppat.0040017.g003
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Mannose Receptor Mediates Dengue Infectioninfection. Anti-MR antibody signiﬁcantly blocked DV infec-
tion of IL-4-treated MDMØ (p¼0.008) in all donors tested (6
donors; Figure 7A shows data from one representative
donor). Normal goat serum control did not inhibit infection,
suggesting that the MR may be a new functional receptor
contributing to DV infection of human MØ. Production of
infectious virus (pfu/ml) by these cells at 2 d post infection
was reduced by 60%–95% with either mannan or anti-human
MR antibody (Figure 7C), indicating that attachment and/or
entry via this receptor is required for productive infection.
The goat anti-human MR antibody blocked mannosylated
BSA-FITC binding to both IL-4-treated MDMØ and 3T3 cells
transfected with human MR (Figure S1).
Mannan, which blocks MR, DC-SIGN and other receptors
with speciﬁcity for mannose, also blocked DV infection of
MDMØ (Figure 7A and 7B). We tested the ability of several
different anti-DC-SIGN antibodies to block infection of
MDMØ. Antibodies against DC-SIGN have been shown by
others to block DV infection of DC [3,4]. Interestingly, some
anti-DC-SIGN monoclonal antibodies also blocked DV infec-
tion of IL-4-treated MDMØ (Figure 7B), and to a similar degree
to that observed blocking with mannan or anti-MR antibodies.
Discussion
We have shown for the ﬁrst time that MR is a functional
receptor for DV infection of human MØ. Binding of the MR
to DV surface glycoproteins was mediated via the lectin
activity of the CRD binding to glycans on the DV E protein.
Gain of function binding data showed that surface expression
of human MR on 3T3 cells was sufﬁcient to confer DV
binding. Antibodies speciﬁc for the MR signiﬁcantly blocked
both infection of MDMØ and the production of infectious
virus in these cells. FACS analysis showed surface MR
expression increased over 4-fold following IL-4 treatment of
monocytes, corresponding with a similar fold increase in
percent infected cells. Thus, the MR provides a potential link
explaining the increase in MØ permissiveness to DV when
stimulated by IL-4 or IL-13. We hypothesise that the MR may
Figure 4. DV Binds to Cells Transfected with Human MR or DC-SIGN
The expression levels of (A) MR and (B) DC-SIGN on cells transfected with MR (3T3.hMR), DC-SIGN (3T3.DC-SIGN), or vector only (3T3) were assessed by
flow cytometery. Receptor expression was detected with 15–2 (anti-hMR) or 120507 (anti-DC-SIGN) antibodies (pale and dark blue lines). Matched
isotype control (purple and green lines) and secondary antibody only (brown and red lines) staining is included. Binding of NGC DV2 to cells transfected
with (C) vector only (3T3), (D) MR (3T3.hMR), and (E) DC-SIGN (3T3.DC-SIGN) for 90 min on ice was detected by flow cytometry. The histograms show the
binding of anti-DV2 antibody (3H5; brown and green lines) and isotype matched control antibody (blue and red lines). The relative fluorescence
intensity was measured by FACSCalibur analysis and the data are normalised and presented as percent of maximum. Representative data from one of
two independent experiments are shown.
doi:10.1371/journal.ppat.0040017.g004
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Mannose Receptor Mediates Dengue Infectionplay a role in at least one of the stages of DV infection of
human MØ. The ﬁrst stage of virus entry into a cell is
attachment, and the mechanism by which MR enhances the
efﬁciency of DV entry could be by increasing virus attach-
ment, as suggested for DC-SIGN and DV. As the MR can be
internalized by macropinocytosis, pinocytosis, receptor-
mediated endocytosis and phagocytosis, its role could also
be in increasing the rate of DV internalisation, the second
stage of virus entry. Analogous to the proposed mechanism of
Fc-receptor enhancement of DV-antibody complex attach-
ment/uptake in antibody-dependent enhancement, the pres-
ence of receptors such as MR or DC-SIGN, which enhance
virus attachment/entry, may play a signiﬁcant role in vivo.
Anti-DC-SIGN monoclonal antibodies were also able to
block DV infection of MDMØ, as has been seen previously in
MDDC. The anti-DC-SIGN antibodies that blocked DV
infection of IL-4 treated MDMØ to the greatest degree
(DC28 and 120612) are known to cross react with DC-SIGNR.
We hypothesise that the different speciﬁcities of the mono-
clonal antibodies may explain why some but not all block DV
infection of MØ. These ﬁndings corroborate data by Tassa-
neetrithep et al. [4] examining blocking of DV infection of
THP-1 cells transfected with either DC-SIGN or DC-SIGNR,
where the same two anti-DC-SIGN antibodies (but not others)
blocked infection. The observation that antibodies to either
MR or DC-SIGN can inhibit infection to such an extensive
degree suggests that DV is likely to be using both MR and DC-
SIGN for entry on cells that express both. It is difﬁcult to
assess the relative (and possibly differing) roles of MR and DC-
SIGN in DV infection of primary MØ or DC that express both;
however, our observation that expression of MR on 3T3 cells
confers DV binding suggests that MR can mediate direct
recognition of DV by myeloid cells. DC-SIGN has been
suggested to function in DV attachment rather than internal-
isation, raising the possibility of another receptor being
involved in the internalisation step of infection. At this stage
the simplest hypothesis that explains the above ﬁndings in
primary cells expressing both MR and DC-SIGN is that DC-
SIGN is required for DV attachment and MR for internal-
isation. Alternatively, these receptors may function simulta-
neously and even co-operatively throughout the infectious
process. Further studies on the cellular expression, location in
the cell and ligand speciﬁcity of these receptors may provide
clues as to the absolute roles they play in DV infection.
MR is ideally poised to act as a DV entry receptor given its
constitutive recycling to the cell surface and ability to
promote ligand internalisation via both endocytic and
phagocytic pathways. While DC-SIGN mainly localises to the
Figure 5. IL-4 and IL-13 Enhance Monocyte and MØ Susceptibility to DV Infection
Monocytes isolated from human peripheral blood were either treated with IL-4 or IL-13 or were left untreated for 2 d (day 2 MDMØ) prior to infection
with dengue virus. Two days following infection, permeabilized cells were stained with antibody to dengue E protein (green) and nuclei stained with
DAPI (blue).
(A) Low power image. (B) Single DV-infected cell confocal image showing DV protein distributed throughout the cytoplasm. Image represents a single
x-y section through the middle of a cell. Fluorescence images are shown next to the corresponding transmission image. (C) The percentage of cells
infected was counted by microscopy. Each line represents a single donor. (D) Monocytes were matured into MDMØ by 7 d incubation prior to treatment
with IL-4 for 2 d (day 9 MDMØ). Cells were infected with DV and stained, and percent infected cells calculated.
doi:10.1371/journal.ppat.0040017.g005
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Mannose Receptor Mediates Dengue Infectionplasma membrane [22], ;85% of cellular MR is located
within the endocytic pathway [8] as a large intracellular
receptor pool from which internalised receptor is rapidly
replaced. In addition to expression on MØ, certain sub-
populations of DC, including dermal DC in human skin,
express the MR [22], in which case it may be involved in
antigen delivery for presentation [23,24]. MR is expressed on
MØ as well as cells lining venous sinuses in human spleen [25]
and is therefore well located to act as a receptor for DV
replication in these physiologically relevant target cells. Here
it may have roles in clearance or adhesion, but also
potentially in vascular leakage. A soluble form of MR has
been found to be abundant in mouse [26] and human plasma
(unpublished observations, L. Martinez-Pomares) and its CR
domain has targets in the spleen. Binding of ligands by
soluble MR can result in the transport of MR ligands to the B
cell follicles, which may lead to clearance or enhanced
presentation of viral antigen depending on TLR co-stimula-
tion. Soluble MR could also potentially play a role in
protection of virus from complement activation. Further
elucidation of the exact role of MR in the attachment/entry/
infectivity of DV will be a fundamental step in gaining a
better understanding of DV pathogenesis.
MR and DC-SIGN both contain lectin domains, but differ
distinctly in terms of ligand speciﬁcity, with MR binding
terminal mannose, fucose and N-acetyl glucosamine, and DC-
SIGN binding mannose within high-mannose oligosacchar-
ides and fucosylated glycans [8,27,28]. Glycosylation endows
unique properties to glycoproteins and can play a signiﬁcant
role in immunity. Recent observations using DV mutants in
one or both of the N-linked glycosylation motifs have shown
that N-linked glycosylation at Asn-67 is required for virus
growth in mammalian cells [29]. In addition, new data by
Mondotte and colleagues showed that DV lacking carbohy-
drate at Asn-67 had reduced capacity to infect MDDC [30].
This, combined with the observation that MDDC express both
DC-SIGN and MR [22], and our demonstration that the
presence of MR alone is sufﬁcient to confer DV binding to
transfected cells, suggest that glycosylation at Asn-67 may be
relevant for mediating MR binding, in addition to that of DC-
SIGN. While the sE may contain sulphated glycans, it was not
bound by the CR fusion protein (Figure 1B), and so the CR
domain of the MR is not expected to contribute to the
binding of MR to DV. Our deglycosylation studies on sE show
that it bears either complex or hybrid N-linked glycans.
Terminal fucose is a reported ligand of MR and as such is the
likely ligand on this source of DV antigen. A more detailed
glycan analysis of DV grown in human MØ will be an
important challenge for the future.
We expanded our study of the interaction of MR with DV
by demonstrating binding of CRD4-7-Fc to all four serotypes
of DV. Differences in glycosylation between DV serotypes,
and more broadly between different ﬂaviviruses, may be
relevant for interaction with lectin receptors such as MR and
DC-SIGN. We showed that MR can bind in ELISA to Japanese
encephalitis virus and tick-borne encephalitis virus, both of
which are reported to have glycosylated envelope proteins.
In this report we have shown that the type 2 cytokines IL-4
and IL-13 enhance the susceptibility of MDMØ to DV
infection. The mechanisms resulting in increased infection
in response to IL-4 and IL-13 are unknown. Analysis of IL-4-
treated human monocytes showed that these cells are
characterised by the overexpression and enhanced function
of several endocytic receptors, including scavenger and C-
type lectin receptors [18]. Functional ligand binding and
transcriptional proﬁling studies [19,31] reveal that the MR is
markedly upregulated on alternatively activated MØ.
A number of important conditions result in polarised
activation of MØ phenotype. Our ﬁndings make it highly
relevant to understand the clinical and epidemiological
signiﬁcance of a Th2 environment on DV infection, patho-
genesis, and enhancement and in the development of a
desirable vaccine response. It will be of great interest to
examine the broader context in which dengue pathogenesis
occurs by considering the effects on DV disease of settings
that induce Th2 cytokines, including co-infection with
parasites, the presence of immune complexes and allergy
(e.g. asthma). There are few studies into the implications of
co-incidence of parasitic infections or allergic disease and
dengue infection. Guzman and colleagues showed signiﬁ-
Figure 6. IL-4 Treatment Enhances Surface Expression of MR and DC-
SIGN on Human MDMØ
The effects of 2 d IL-4 treatment (25ng/ml) of human monocytes on
surface expression levels of (A) MR and (B) DC-SIGN were assessed by
flow cytometery. Receptor expression was detected with 15–2 (anti-hMR)
or 120507 (anti-DC-SIGN) antibodies (black lines) on untreated cells
(open histogram) and IL-4-treated cells (filled histogram). Matched
isotype control (grey lines) staining is included. The relative fluorescence
intensity was measured by FACSCalibur analysis and the data are
normalised and presented as percent of maximum. Representative data
from one of eight donors are shown.
doi:10.1371/journal.ppat.0040017.g006
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patients compared with controls [32]. During secondary
dengue infection when anti-DV antibody is present, the
study of DV interactions with MØ stimulated through FccR
ligation (‘type II’ activated MØ), may be of particular
relevance. Given the risk of antibody-dependent enhance-
ment to vaccine trials, a Th2 environment (which is known to
inﬂuence humoral responses and FcR expression [33,34]) may
be a contributing factor to vaccine efﬁcacy and DV patho-
genesis and as such will require further examination.
Materials and Methods
Viruses and cell lines. 16681 and New Guinea C (NGC) strains of
DV2 (both gifts from E. Gould, Oxford Centre for Ecology and
Hydrology, UK) were propagated in the Aedes albopictus–derived C6/36
cell line (a gift from Armed Forces Research Institute of Medical
Sciences, Thailand). Virus titres were obtained by plaque assay on
LLC-MK2 monkey kidney cells (a gift from Armed Forces Research
Institute of Medical Sciences, Thailand), as described previously [35].
16681 strain DV2 grown in Vero cells, precipitated with polyethylene
glycol, puriﬁed on a sucrose gradient and inactivated with form-
aldehyde was from Biodesign. Hawaii strain DV1, NGC strain DV2, H-
87 strain DV3 and H-241 strain DV4 grown in C6/36 cells were
precipitated with 7% polyethylene glycol and inactivated with beta-
propiolactone (Biodesign). Human 293T-HEK cells (ATCC) were
maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Invi-
trogen) supplemented with 2mM glutamine, 0.1mg/ml streptomycin,
100U/ml penicillin and 10% heat inactivated fetal calf serum (FCS).
A stable NIH3T3 cell line expressing the human MR (3T3.hMR) was a
gift from Gordon Brown (University of Cape Town, South Africa) and
Philip Taylor (University of Cardiff, UK), made using the protocol
described previously [21]. Human MR was ampliﬁed from cDNA
derivedfrom humanmRNA. High expressing cloneswere selectedafter
limiting dilution in 96 well plates. Control 3T3 cells expressing the
vector only were prepared in parallel. Production of stable NIH3T3
expressing the murine MR (3T3.mMR) has been described previously
[21]. These NIH3T3 transfectants were maintained in DMEM (Invi-
trogen) supplemented as above and with 0.6mg/ml geneticin (Invitro-
gen). NIH3T3 cells transfected with DC-SIGN (3T3.DCSIGN) were
obtained through the NIH AIDS Research and Reference Reagent
Program (from Drs Thomas Martin and Vineet KewalRamani) and
maintained in similar DMEM medium without geneticin.
Reagents. Fc chimeric proteins (derived from the murine MR) and
the hemagglutinin-tagged form of MR (MR-HA) were prepared by
Richard Stillion as described previously [7,36]. Mannan was from
Saccharomyces cerevisiae (Sigma). Antibodies were speciﬁc for DV2 E
protein (3H5; a gift from Dale Greiner), MR (goat anti-hMR; a kind
gift from Philip Stahl (Washington University School of Medicine, St.
Louis, MO), DC-SIGN (120507), DC-SIGNR (120604) and both DC-
SIGN and DC-SIGNR (DC28 and 120612) (all from R&D Systems). The
speciﬁcity of anti-hMR antibody is examined in Figure S1.
Preparation of primary cells. For the generation of MDMØ and
MDDC, human PBMC were isolated from buffy coats (NHS Blood and
Transport) by centrifugation over a Ficoll-PaqueTM PLUS (Amer-
sham) gradient, according to standard protocols. Adherent mono-
cytes, isolated as described previously [37], were cultured in X-VIVO
medium (BioWhittaker) with 1% heat-inactivated autologous plasma
to allow differentiation into MDMØ.T h e s ec e l l sw e r e.95%
macrophages phenotypically (CD14þ, CD16-, CD86þ,H L A - D R þ,
CD3 ) (data not shown). For the generation of MDDC, recombinant
human IL-4 (25ng/ml; Peprotech) and GM-CSF (50ng/ml; Peprotech)
were added to monocytes in X-VIVO medium (BioWhittaker) with
1% heat-inactivated autologous plasma and the cells cultured for 4 d.
The use of human blood was approved by the central Oxford
University research ethics committee (MSD/IDEC/C1/2006/32).
DV infection. Monocytes were treated with recombinant human IL-
4 (25ng/ml; Peprotech) or IL-13 (10ng/ml; Peprotech) for 2 d then
infected with mosquito cell-grown 16681 DV2 virus. After 1 h the viral
supernatant was replaced with cell culture medium without cytokine
and the cells incubated for 2 d then ﬁxed with 4% paraformaldehyde.
Figure 7. Anti-MR and Anti-DC-SIGN Antibodies Inhibit the Ability of DV2
to Infect IL-4-Treated Monocytes
(A) IL-4-treated human monocytes were incubated in triplicate wells with
medium alone (no block), 2mg/ml mannan, titrations of goat anti-human
MR antiserum, or with normal goat serum (NGS). Treated cells were
infected with mosquito cell–grown 16681 DV2 at a multiplicity of
infection of 0.5 in the presence of these inhibitors, incubated for 48 h
and fixed.
(B) Monocytes were treated in triplicate wells, as above, including
blocking with monoclonal antibodies specific for DC-SIGN (120507), DC-
SIGNR (120604), and both DC-SIGN and DC-SIGNR (DC28 and 120612) or
isotype controls (all at 5ug/ml) prior to infection with mosquito cell–
grown 16681 DV2 at a multiplicity of infection of 0.04 in the presence of
these inhibitors. Following fixation, cells were immunolabelled with anti-
DV E protein monoclonal antibody 3H5 and counted using a fluorescent
microscope, and percent of cells infected calculated. Data are expressed
as mean and SD of triplicate wells. Representative data from one of
multiple donors are shown.
(C)Thetitreofinfectiousvirusinthecellsupernatantat48hpostinfection
was determined by plaque assay. Due to variation between donors, the
titre at 48 h in the absence of block was normalised to 100. Each data
point is the average of three infectedwells, each plaqued in triplicate, and
the results from six donors are shown in this graph (mean represented by
a bar). The p value was calculated by unpaired, two-tailed t test.
doi:10.1371/journal.ppat.0040017.g007
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various blocking reagents for 40 min at 378C before the addition of
16681 DV2 virus (in the presence of blocking agent).
Detection of MR fusion protein binding to DV antigen ELISA. 96-
well Maxi-Sorp plates were coated overnight with DV antigens (50ug/
ml C6/36-grown NGC DV2 and 20ug/ml sE, or as speciﬁed in Figure 1)
in phosphate-buffered saline (PBS; 138mM NaCl, 2.7mM KCl, 8mM
Na2HPO4, 1.5mM KH2PO4, [pH 7.4]) at 48C in triplicate. Wells were
blocked with 0.5% immunoglobulin-free BSA (Sigma) before in-
cubation with 15 ug/ml MR-HA, 2ug/ml human Fc-fusion MR domain
proteins or 15ug/ml rabbit anti-DV1–4 antibody for 2 h at room
temperature in Tris buffered saline (TBS; 10mM TrisHCl, pH 7.4,
0.154 M NaCl, 0.05% Tween 20) containing 10mM CaCl2. For
competitive binding studies MR fusion proteins were pre-incubated
for 30 min on ice in TBS containing 1M NaCl and 10mM CaCl2 in the
presence of 2mM D-mannose, 2mM L-fucose or 2mM galactose, or
TBS containing 10mM EDTA. The wells were washed 6 times and
binding of the Fc-fusion proteins was detected by incubating the wells
with an alkaline phosphatase-conjugated anti-human antibody
(1:1,000 dilution), visualized using 1mg/ml 4-Nitrophenyl phosphate
disodium salt hexahydrate in 100mM Tris, 100mM NaCl, 5mM MgCl2,
pH9.5, and the absorbance was read at 405nm. The wells with HA-
tagged protein were incubated with 10ug/ml of MR5D3 (rat anti-
mouse MR; [21]) for 1 h at room temperature followed by an alkaline
phosphatase-conjugated anti-rat antibody (1:1,000 dilution) and
visualized as above. The wells with rabbit anti-DV1–4 were incubated
with an alkaline phosphatase-conjugated anti-rabbit antibody
(1:1,000 dilution) and visualized as above. Wells coated with mannan
and SO43GalNAc-PAA (Lectinity) were included as a positive control
for proteins containing the CRD4–7 and CR domains respectively
(data not shown). We veriﬁed that DV2 ligands had coated all of the
wells equally by using direct ELISA detection of DV antigens 3H5
(10ug/ml) followed by a goat anti-mouse alkaline phosphatase-labelled
(1:1,000 dilution) secondary antibody and visualised as above.
Blot overlays. CRD4–7 binding to sE was investigated by blot
overlay by running 0.9ug sE protein and 0.9ug sE protein
deglycosylated with peptide: N-glycosidase F (New England Biolabs)
on 10% SDS-PAGE, and subsequently transferring proteins to
Hybond C-Extra nitrocellulose membranes (Pharmacia). Blots were
blocked for 1 h in 0.5% skimmed milk powder in TBS containing
10mM CaCl2 (blocking/washing solution). Blots were probed with 1ug/
ml MR CRD4–7-Fc in the absence or presence of either 2mM D-
mannose, 2mM L-fucose or 20mM EDTA for 2 h, and then washed
three times with blocking solution. Binding was detected with 1ug/ml
horseradish peroxidase-conjugated anti-human IgG antibody (Vector
Laboratories) and visualized by chemiluminescence. Blots probed in
the presence of inhibitors were washed 3 times and reprobed with
MR CRD4–7-Fc in the absence of inhibitor. Blots were stripped by
incubation in 63mM Tris, pH 6.7, 2% SDS and 100mM 2-
mercaptoethanol at 508C for 30 min, re-blocked and probed with
the anti-DV E-protein antibody, 3H5, at 10ug/ml. Binding was
detected with 10ug/ml horseradish peroxidase-conjugated anti-mouse
IgG antibody and visualized by chemiluminescence.
Production of recombinant sE protein. An open reading frame
consisting of the last 20 aa of C-protein, the entire prM protein, and E
protein truncated by 96 amino acids at the C-terminus and containing
a hexahistidine tag was ampliﬁed by PCR from cDNA prepared from
DV2 strain 16681. The expression cassette was cloned in the
mammalian expression vector pLEX [38] and transfected into human
293T-HEKcellsculturedinOptimem(Invitrogen),andsEwaspartially
puriﬁed from the supernatants of these cultures by Ni-chelation
afﬁnity chromatography (Figure 3A). The identity of the protein was
conﬁrmed by mass-spectrometric analysis of peptides resulting from
tryptic digest of the excised SDS-PAGE band (data not shown).
sE glycan analysis. Glycans were released from approximately 25ug
of recombinant soluble dengue virus E-glycoprotein and labelled by
reductive amination with the ﬂuorophore 2-aminobenzamide [39,40].
The glycans were processed through NP-HPLC and the retention
times for the individual glycans were converted to glucose units (GU)
using a standard dextran curve [41]. These were then compared with a
databaseof experimental values(http://glycobase.ucd.ie/cgi-bin/public/
glycobase.cgi) and initial assignments made were conﬁrmed following
digestions of the glycans with an array of exoglycosidase enzymes [40].
Flow cytometry. FACS was performed according to conventional
protcols at 48C in the presence of 2mM NaN3. Non-speciﬁc binding
sites on cells were blocked with PBS containing 5% heat-inactivated
rabbit serum, 5% heat-inactivated goat serum, 0.5% BSA and 5mM
EDTA (blocking buffer) before the addition of primary antibodies.
Surface expressed MR and DC-SIGN was detected using 10ug/ml 15–2
(Serotec) and 120507 (R&D Systems) monoclonal antibodies, respec-
tively, and was compared with an isotype control (Serotec). Surface
bound DV was detected using 10ug/ml 3H5. The primary antibodies
were detected using Alexaﬂuor 488-conjugated anti-mouse antibody
(Molecular Probes) diluted 1:200 in blocking buffer. Cells were ﬁxed
with 1% paraformaldehyde in PBS before analysis. Binding was
quantiﬁed on a FACSCalibur ﬂow cytometer and data from ;10,000
cells were routinely acquired for each sample. Data were analysed
using FlowJo software (Treestar). Percent of max represents the
number of events normalised according to FlowJo algorithms. Fold
increase in receptor expression was measured by geometric mean
ﬂuorescent intensity of speciﬁc receptor antibody staining for IL-4-
treated cells divided by untreated cells.
Cell binding assays. Cells suspensions were prepared by scraping
cells to preserve receptor expression at the cell surface. Mosquito cell-
grownNGCDV2(1.5310
6pfu/ml)ormediawasincubatedwithcells(43
10
6) at a multiplicity of 0.35 infectious virions per cellfor 80 min on ice.
Unbound virus was washed away with cold media, the cells were ﬁxed
with 1% paraformaldehyde in PBS, and surface bound virus detected
with anti-DV E-protein antibody by ﬂow cytometry as described above.
FITC-labelled, mannosylated or galactosylated BSA (5ug/ml; Sigma)
was incubated for 90 min at 378C with primary human MDMØ or 3T3
transfectants plated on tissue culture-treated plastic. For blocking
studies cells were pre-incubated with mannan (2mg/ml), normal goat
serum (NGS) or goat-anti hMR antibody for 20 min at 378C. After
incubation cells were washed with PBS, harvested using PBS
containing 5mM EDTA and lidocaine (4mg/ml) and ﬁxed in 2%
paraformaldehyde in PBS. Binding was quantiﬁed by a FACSCalibur
ﬂow cytometer and analysed using FlowJo software.
Immunoﬂuorescence microscopy. Fixed, DV-infected cells were
permeabilised with 0.5% Triton-X and stained with 10ug/ml 3H5
followed by an Alexaﬂuor 488-labelled secondary anti-mouse IgG
antibody (Molecular Probes) and the nuclei stained with DAPI.
Stained coverslips were mounted in DakoCytomation ﬂuorescent
mounting medium (Dako), and analyzed using either CCD1 (Axio-
plan) and CCD camera (Spot) or a META
TM confocal microscope
linked to LSM 510
TM software (Carl Zeiss MicroImaging, Inc.).
Confocal images were acquired sequentially using the multitrack
conﬁguration of the Zeiss META
TM to avoid bleed-through between
ﬂuorescence channels, and the appropriate controls with and without
primary antibody were performed. Additional image processing was
performed using Adobe Photoshop 7. The image is presented as
single two-dimensional x-y sections and the corresponding trans-
mission image. At least twelve ﬁelds (600–1,000 individual cells) were
counted by ﬂuorescent micrsocopy.
Statistical analysis. Statstics were calculated using GraphPad
PRISM(version 2.0; GraphPadSoftware,San Diego, CA) and Microsoft
Excel. Two-tailed Student’s t tests were used to calculate p values.
Supporting Information
Figure S1. Goat Anti-Human MR Antibody Speciﬁcally Blocks
Mannosylated BSA-FITC Binding to Cells Expressing Human MR
Found at doi:10.1371/journal.ppat.0040017.sg001 (2.1 MB TIF).
Table S1. Effects of Cytokines and Cytokine Combinations on DV
Infection of Monocytes
Found at doi:10.1371/journal.ppat.0040017.st001 (35 KB RTF).
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